Krystal Biotech (Krystal Biotech) Interest Coverage : N/A (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Krystal Biotech Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Krystal Biotech's Operating Income for the three months ended in Mar. 2024 was $5.82 Mil. Krystal Biotech's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Krystal Biotech Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Krystal Biotech's Interest Coverage or its related term are showing as below:

KRYS's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 138.73
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Krystal Biotech Interest Coverage Historical Data

The historical data trend for Krystal Biotech's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Krystal Biotech Interest Coverage Chart

Krystal Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

Get a 7-Day Free Trial

N/A

Krystal Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Coverage	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Krystal Biotech's Interest Coverage

For the Biotechnology subindustry, Krystal Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Krystal Biotech's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Interest Coverage falls into.

Krystal Biotech Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Krystal Biotech's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Krystal Biotech's Interest Expense was $0.00 Mil. Its Operating Income was $-97.23 Mil. And its Long-Term Debt & Capital Lease Obligation was $6.62 Mil.

GuruFocus does not calculate Krystal Biotech's interest coverage with the available data.

Krystal Biotech's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Krystal Biotech's Interest Expense was $0.00 Mil. Its Operating Income was $5.82 Mil. And its Long-Term Debt & Capital Lease Obligation was $6.47 Mil.

GuruFocus does not calculate Krystal Biotech's interest coverage with the available data.

The higher the ratio, the stronger the company's Financial Strength is.

Krystal Biotech (NAS:KRYS) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Krystal Biotech Interest Coverage Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Krystal Biotech (Krystal Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (NAS:KRYS) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

4KB:Germany

Address

2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203

Website

https://www.krystalbio.com

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future.

Executives

Krish S Krishnan	director, 10 percent owner, officer: President and CEO	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Suma Krishnan	director, 10 percent owner, officer: Chief Operating Officer	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Catherine Mazzacco	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Daniel Janney	director	PO BOX 7414, JACKSON WY 83002
Andrew C. Orth	officer: Chief Commercial Officer	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Kathryn Romano	officer: Chief Accounting Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Dino A Rossi	director	61 WATROO POINT, DANIEL ISLAND SC 29492
Everett Rand Sutherland	director	29 HARTWELL AVENUE, LEXINGTON MA 02421
Christopher Mason	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jing L. Marantz	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Julian S Gangolli	director	4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Jennifer Chien	officer: Chief Commercial Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Antony A Riley	officer: Chief Financial Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
R Douglas Norby	director	C/O MAGNACHIP SEMICONDUCTOR, INC., 20400 STEVENS CREEK BOULEVARD, SUITE 370, CUPERTINO CA 95014
Sun Pharma (netherlands) B.v.	10 percent owner	POLARISAVENUE 87, 2132 JH HOOFDDORP P7 00000